deuruxolitinib
concert pharma
['thrive,aa1', 'concert']
eadv 2022 late breaking news. we re excited to share our ctp-543 thrive-aa1 phase 3 data in patients with #alopeciaareata during the late -breaking news session at the 2022 #eadvcongress 
We apply our industry-leading expertise in deuterium chemistry to create and develop innovative drug products that address important patient needs.